| Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. | |
| | |
MedLine Citation:
|
PMID: 14727969 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients presenting with unstable angina pectoris or non-Q-wave myocardial infarction (MI), if treated inadequately, are at a high risk of MI and subsequent mortality. The use of intravenous small molecule glycoprotein IIb/IIIa inhibitors along with standard therapeutic management options improves outcome. Since the publication of the Thrombolysis in Myocardial Ischemia IIIB, Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) and Fragmin and Fast Revascularization during InStability in Coronary artery disease II (FRISC II) studies, there is great debate about the advantages of following an early 'invasive' treatment option with coronary angiography and revascularization after initial medical therapy compared with the 'conservative' approach, where angiography is reserved for those who remain symptomatic. The Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy--Thrombolysis in Myocardial Infarction 18 (TACTICS-TIMI 18) study has helped to resolve some of the controversies since it was designed with more current medical (early and routine use of tirofiban) and revascularization (use of stents during percutaneous coronary interventions) options as part of the invasive treatment protocol. This study indicated that an early invasive strategy in risk stratified patients combined with early use of tirofiban with standard medical therapy significantly improves outcome and appears well tolerated. |
| | |
Authors:
|
Ganesh Manoharan; A A Jennifer Adgey |
Related Documents
:
|
10485409 - Two-year assessment by exercise thallium scintigraphy of myocardial revascularization u... 12643399 - Revascularization in severe ventricular dysfunction (15% < or = lvef < or = 30%): a com... 10678439 - Factors influencing clinical outcomes after revascularization in the asymptomatic cardi... 11431659 - Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or trans... 9930489 - Neovascularization after transmyocardial laser revascularization in a model of chronic ... 17410069 - Determinants of late outcome after minimally invasive direct coronary artery bypass. 15486129 - Idiopathic enlargement of the right atrium: 23 year follow up of a familial cluster and... 2335849 - Effects of a thromboxane a2 synthetase inhibitor on ventricular fibrillation threshold ... 17041699 - Chronic pseudoaneurysm and coarctation of the aorta: a rare delayed complication of tra... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of cardiovascular drugs : drugs, devices, and other interventions Volume: 2 ISSN: 1175-3277 ISO Abbreviation: Am J Cardiovasc Drugs Publication Date: 2002 |
Date Detail:
|
Created Date: 2004-01-19 Completed Date: 2004-04-14 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100967755 Medline TA: Am J Cardiovasc Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 237-43 Citation Subset: IM |
Affiliation:
|
Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, Northern Ireland. gmanoharan@msn.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina, Unstable
/
drug therapy,
economics,
therapy* Angioplasty, Balloon Aspirin / therapeutic use Dalteparin / therapeutic use Drug Therapy, Combination Fibrinolytic Agents / therapeutic use Heparin / therapeutic use Humans Myocardial Infarction / drug therapy Myocardial Ischemia / drug therapy, therapy Randomized Controlled Trials as Topic Risk Assessment Thrombolytic Therapy Tyrosine / analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Dalteparin; 0/Fibrinolytic Agents; 144494-65-5/tirofiban; 50-78-2/Aspirin; 55520-40-6/Tyrosine; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New targets for antithrombotic drugs.
Next Document: Pharmacotherapy of obesity: currently marketed and upcoming agents.